Poggi Maurizio, Samperi Irene, Mattia Lorenza, Di Rocco Arianna, Iorio Cristina, Monti Salvatore, Pugliese Giuseppe, Toscano Vincenzo
Department of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.
Endocrine-Metabolic Unit, Sant'Andrea University Hospital, Rome, Italy.
Front Mol Biosci. 2020 Jan 29;6:162. doi: 10.3389/fmolb.2019.00162. eCollection 2019.
Thalassemia Major (TM) is a complex pathology that needs a highly skilled approach. Endocrine comorbidities are nowadays the most important complications, including hypogonadism, hypothyroidism, diabetes mellitus, and bone diseases. Recent works stated that there could be a relevant prevalence of adrenal insufficiency (AI) present in TM, and this fact may become crucial, especially in case of major stressful events. Test the reliability of the standard test to diagnose AI in a group of TM and correlate it with clinical, hematological, and radiological data. We evaluated endocrine damages and the efficacy of iron chelation therapy in 102 patients affected by TM. AI was assessed by tetracosactide (Synacthen) 1 mcg iv (low-dose test, LDT) stimulation test. Patients with a subnormal response (peak cortisol < 500 nmol/L) were followed up to 5 years to check the symptoms and signs of AI. We found AI in 13.7% of the population studied. We did not find any correlation between AI and all data evaluated. Only female gender seems to be a protective factor. A follow up of the patients affected by AI showed no signs of adrenal crisis, in spite of no replacement therapy. Our study shows a relevant prevalence of AI in TM, especially in males. The absence of an adrenal crisis, in spite of no replacement therapy, during the long-term follow up, seems to underline that current methods to evaluate AI, in TM, should consider a different and specific diagnostic test or different cut off for diagnosis.
重型地中海贫血(TM)是一种复杂的病症,需要高度专业的治疗方法。内分泌合并症如今是最重要的并发症,包括性腺功能减退、甲状腺功能减退、糖尿病和骨骼疾病。最近的研究表明,TM患者中可能存在相当比例的肾上腺功能不全(AI),这一事实可能至关重要,尤其是在发生重大应激事件时。在一组TM患者中测试诊断AI的标准试验的可靠性,并将其与临床、血液学和放射学数据相关联。我们评估了102例TM患者的内分泌损害及铁螯合治疗的疗效。通过静脉注射1微克替可克肽(辛纳科)(低剂量试验,LDT)刺激试验评估AI。反应低于正常水平(皮质醇峰值<500 nmol/L)的患者随访5年,以检查AI的症状和体征。我们在所研究的人群中发现13.7%的人存在AI。我们未发现AI与所有评估数据之间存在任何相关性。只有女性性别似乎是一个保护因素。对AI患者的随访显示,尽管未进行替代治疗,但未出现肾上腺危象的迹象。我们的研究表明TM患者中AI的患病率较高,尤其是男性。在长期随访中,尽管未进行替代治疗,但未出现肾上腺危象,这似乎强调了目前在TM中评估AI的方法应考虑采用不同的特异性诊断试验或不同的诊断临界值。